Novartis India has launched Pluvicto, a precision radiotherapy for prostate cancer. Pluvicto is the country's first regulatory authority-approved radioligand therapy for eligible patients with prostate-specific membrane antigen (PSMA)-positive prostate cancer.
Designed to precisely target prostate cancer cells while minimising exposure to healthy tissues, Pluvicto introduces a new treatment approach for metastatic prostate cancer, a disease that continues to place a significant physical and emotional burden on patients and families across India.
Novartis India is a pharmaceutical company. The business operations of the Company include Pharmaceuticals, Generic, over the counter (OTC) and Animal Health.
| Company Name | CMP |
|---|---|
| Redington | 275.75 |
| Amrapali Industries | 32.28 |
| Adani Enterprises | 3001.60 |
| Rashi Peripheral | 748.95 |
| PDS | 364.70 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: